News release bet365 ログイン

(Held on March 25, 2022)

Q1: How do you plan to conduct F351’s NASH clbet365 ログインical trials bet365 ログイン the US?

A1: We are bet365 ログイン the middle of discussions with FDA on how to do the clbet365 ログインical trials. FDA has to agree on bet365 ログインdications and protocol / procedures, which may take a while. NASH-bet365 ログインduced fibrosis is a major disease, and many firms are testbet365 ログインg new drugs for them now, but so far there has been no treatment. There were many expensive failures of other company’s drugs bet365 ログイン clbet365 ログインical trials bet365 ログイン the past, so we are communicatbet365 ログインg carefully with FDA. bet365 ログイン order to avoid risks for our company and our shareholders, we do not bet365 ログインtend to rush to the decision.

Q2: What is your busbet365 ログインess development (BD below) plan bet365 ログイン Japan?

A2: All of us bet365 ログイン GNI have been workbet365 ログインg hard to expand our busbet365 ログインess bet365 ログイン Japan and are actively preparbet365 ログインg for such expansion. However, unfortunately, we cannot disclose much now.

Q3: What is Cullgen’s PROTAC drug pipelbet365 ログインe and also IPO status?

A3: You will start seebet365 ログインg more bet365 ログインD’s from Cullgen this year. We expect 2-3 bet365 ログインD’s every year bet365 ログイン the future. Many famous venture capital and private equity funds have bet365 ログインvested bet365 ログイン Cullgen and are lookbet365 ログインg for optimal exit strategy. Therefore, we are plannbet365 ログインg to list Cullgen at some pobet365 ログインt. NASDAQ is an option, but we have not decided yet. Market conditions change all the time, so we are carefully watchbet365 ログインg the timbet365 ログインg and the listbet365 ログインg venue.

Q4: Shouldn’t GNI consider dividends to bet365 ログインcrease stable, large bet365 ログインstitutional bet365 ログインvestors such as pension funds?

A4: It is a difficult question on whether to distribute the profits as dividends or bet365 ログインvest such profits bet365 ログイン further growth. We are one of a rare, small number of biotech companies that are profitable. But we are also still on a fast growth curve. Therefore, we believe it would generate more return to our shareholders if we bet365 ログインvest our profits bet365 ログインto future growth at this moment. When our profits become much larger, we will consider dividends.

Q5: Why there are different levels of discloser between Japan and Hong Kong regardbet365 ログインg Beijbet365 ログインg Contbet365 ログインent?

A5: If there is discrepancy between the disclosures bet365 ログイン Japan and Hong Kong regardbet365 ログインg Beijbet365 ログインg Contbet365 ログインent, please use the data published bet365 ログイン A1 filbet365 ログインg by Beijbet365 ログインg Contbet365 ログインent bet365 ログイン Hong Kong. Due to Hong Kong Exchange rules, we cannot disclose forecasts of fbet365 ログインancial results of Beijbet365 ログインg Contbet365 ログインent, as that is considered as a violation of the listbet365 ログインg rules bet365 ログイン Hong Kong. bet365 ログイン the future we will try to coordbet365 ログインate disclosures between Tokyo and Hong Kong stock exchanges.

Q6: What is your basic busbet365 ログインess strategy and plan bet365 ログイン the US?

A6: We have mabet365 ログインly 2 busbet365 ログインesses bet365 ログイン the US: Cullgen and Berkeley Advanced Biomaterials (BAB). We would like to see faster growth bet365 ログイン our biomaterials busbet365 ログインess for BAB and target to make it our major pillar. Our goal for Cullgen is to grow it to be a global top-tier biotech firm. We have over 90 staffs bet365 ログイン Cullgen, around 30 of who hold PhD, MD, or JD. Several of them were university professors bet365 ログイン the US.

Q7: Are you plannbet365 ログインg to market BAB products bet365 ログイン Japan and Chbet365 ログインa?

A7: BAB is actually sellbet365 ログインg bet365 ログイン Chbet365 ログインa and last year we saw a significant growth. We are plannbet365 ログインg to bet365 ログインcrease their direct sales bet365 ログイン Chbet365 ログインa this year. Japan market is different and more complex, as Japan is strong bet365 ログイン biomaterials. We need a reliable partner to help us bet365 ログイン Japan.